Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending February 28, 2023 was $-5.55 Million (a -240.29% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 152.97%
- Annual Consolidated Net Income/Loss for 2022 was $-10.9 Million (a -89.49% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2021 was $-104 Million (a -0.2% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-104 Million (a 1354.5% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending February 28, 2023 was $-8.6 Million (a 37.94% increase compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss decreased by -69.43% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 28 Feb '23 | 30 Nov '22 | 31 Aug '22 | 31 May '22 |
|---|---|---|---|
| $-8.6 Million | $-6.24 Million | $-11.2 Million | $-28.1 Million |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of Organigram Holdings Inc.
Most recent Consolidated Net Income/Lossof OGI including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of Organigram Holdings Inc.
Organigram Holdings Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-5.55 | – | – | – | – |
| 2022 | $3.96 | $-4.81 | $-2.19 | $-3.18 | $-10.9 |
| 2021 | $-1.04 | $-21.72 | $-3.2 | $-52.09 | $-103.73 |
| 2020 | $-26.08 | $-31.14 | $-64.31 | $-5.19 | $-103.94 |
| 2019 | $-0.65 | $-17.34 | $-7.59 | $-4.79 | $-7.15 |
| 2018 | – | – | $22.53 | $14.17 | $17.02 |
| 2017 | – | – | – | – | $-8.51 |
| 2016 | – | – | – | – | $0.65 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic